Esters-buliding-blocks

On November 30, 1983, Naithani, Vinod K.; Schwertner, Eberhard published an article.Related Products of 53838-27-0 The title of the article was Human proinsulin VI. Synthesis of protected segment 46-70 of prohormone. And the article contained the following:

Title protected peptide Ph3C-Gly-Gly-Pro-Gly-Ala-Gly-Ser(CMe3)-Leu-Gln-Pro-Leu-Ala-Leu-Glu(OCMe3)-Gly-Ser(CMe3)-Leu-Gln-Lys(CO2CMe3)-Arg-Gly-Ile-Val-Glu(OCMe3)-Gln-OH was prepared by a series of fragment condensations in solution The final step involved 2 possible mixed anhydride condensations: the coupling of protected fragment 46-64 with protected fragment 65-70 or the coupling of protected fragment 46-59 with protected fragment 60-70. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Related Products of 53838-27-0

The Article related to proinsulin pentacosapeptide, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Related Products of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 26, 2016, Malolanarasimham, Krishnan; Murugan, Ravichandran Narayanasamy; Kedari, Chaitanya Kumar; Tulam, Vijaya Kumar published a patent.Safety of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Acylation process for the preparation of liraglutide. And the patent contained the following:

The invention is related to a process for the preparation of an N-substituted peptide or protein comprising: (a) reacting a peptide or protein with a copper agent to form a copper complex of peptide or protein; (b) converting the copper complex of the peptide or protein obtained in step (a) to the desired N-substituted peptide or protein in an organic solvent or in water or mixtures thereof; and (c) optionally, hydrolyzing the N-substituted peptide or protein obtained in step (b) to obtain the desired N-substituted peptide or protein, wherein the N-substituted peptide or protein is the GLP agonist H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-N6 -[N-(1-oxohexadecyl)-γ-Glu]-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH (liraglutide). The invention provides an alternate acylation process for preparation of liraglutide high yielding, scalable, cost effective, environment friendly and com. viable by avoiding repeated cumbersome and lengthy purification steps. Specifically, the invention is related to process for the preparation of liraglutide comprising: (i) reacting a liraglutide precursor with a copper agent, e.g., CuSO4•5H2O to form a copper complex of liraglutide precursor, (ii) converting the copper complex of liraglutide precursor obtained in step (i) to N-substituted liraglutide precursor by reacting with an N-acylating agent such as 1-Me palmityl glutamic acid or its reactive derivatives (preparation given); and (iii) hydrolyzing the N-substituted liraglutide precursor obtained in step (ii) to obtain liraglutide. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Safety of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to acylation liraglutide preparation, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Safety of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 11, 2017, Deng, Zeping; Chen, Fangjun published a patent.Formula: C9H8F2O2 The title of the patent was Preparation method of 2-(2,6-difluorobenzyl)pyrrolidine. And the patent contained the following:

The method relates to using 2-(2,6-difluorophenyl)acetic acid as initial material, carrying out esterification under action of catalyst, coupling in presence of alkali, opening loop with reducing agents, closing loop in presence of alkali, and reducing with reducing agent to obtain target product. The catalyst is one or more of 4-dimethylamino pyridine, p-Me Ph sulfonic acid, sulfuric acid, and/or thionyl chloride; the reducing agent is one or more of sodium borohydride, potassium borohydride, lithium borohydride, sodium cyano borohydride, lithium aluminum hydride, and/or borane. The compound is important medicine intermediate. The experimental process involved the reaction of Methyl 2-(2,6-difluorophenyl)acetate(cas: 872046-08-7).Formula: C9H8F2O2

The Article related to difluorobenzylpyrrolidine preparation, Heterocyclic Compounds (One Hetero Atom): Pyrroles and Pyrrolizines and other aspects.Formula: C9H8F2O2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 31, 1985, Felix, Arthur M.; Heimer, Edgar P.; Wang, Ching Tso; Lambros, Theodore J.; Swistok, Joseph; Roszkowski, Martin; Ahmad, Mustaq; Confalone, Dianne; Scott, John W. published an article.Product Details of 53838-27-0 The title of the article was Synthesis of thymosin α1 by fragment condensation using tert-butyl side chain protection. And the article contained the following:

Thymosin α1 (I) was prepared by classical methods using 7 tert-Bu side chain protected fragments. Optimum conditions were found for the final DCC/HOBt coupling of the two key intermediates; decapeptide and octadecapeptide. I was purified by two stages of preparative HPLC (partial purification with C8 and final purification with C18 reverse phase silica gel) to give a 30% overall yield for the final four stages of synthesis (including catalytic hydrogenation of octadecapeptide, coupling, deprotection and purification). The product was homogeneous according to thin-layer and paper high voltage electrophoresis, isoelec. focusing anal., thin-layer chromatog. and high-performance liquid chromatog. Amino acid anal., optical rotation, 1H NMR spectroscopy, FAB mass spectroscopy and peptide mapping after tryptic digestion confirmed the structure of thymosin α1. Three minor stereoisomer contaminants were isolated by HPLC and characterized as [D-Lys14]-thymosin α1, [D-Lys17]-thymosin α1 and [D-Ala3]-thymosin α1 resulting from racemization at Lys14, Lys17 and Ala3 during the coupling of the fragments. A final contaminant, isolated by HPLC, was characterized as Nα-isobutyloxycarbonyl-thymosin α1 (15-28), which results from “wrong way opening” of an activated mixed anhydride. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Product Details of 53838-27-0

The Article related to thymosin synthesis fragment condensation, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Product Details of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Fagge, Ibrahim I.; Ahmad, W. Hamdah W.; Zain, Sharifuddin Md; Khan, M. Niyaz published an article in 2018, the title of the article was Kinetics and mechanism of counterionic salt-catalysed piperidinolysis of anionic phenyl salicylate in the presence of cationic-nonionic mixed micelles.Application In Synthesis of Phenyl Salicylate And the article contains the following content:

The quant. correlation of counterion-affinity to aqueous hexadecyltrimethylammonium bromide (HDAB, cationic micelles/nanoparticles) and the counterion-induced HDAB micellar growth, in the presence of different amounts of poly(ethylene glycol hexadecyl ether) (C16E20, nonionic surfactant), was achieved by the use of a semi-empirical kinetic (SEK) method. The values of the ratio of cationic HDAB, as well as mixed HDAB-C16E20, micellar binding constants of X and Br, KX/KBr (= KBrX or RBrX) for X = 4-ClC6H4CO2-, were obtained by the SEK method. The concentration range (0.006-0.015 M) of pure HDAB was found to have no influence on the values of KBrX or RBrX. These observations were also recorded upon addition of a nonionic surfactant, C16E20, in an aqueous solution of HDAB. The mean value of KBrX or RBrX obtained in the presence of pure HDAB (KBrX or RBrX = 50.3) is 2.3 times larger than that in the presence of mixed HDAB-C16E20 (mKBrX or mRBrX = 21.7). From rheometric measurements of aqueous HAD+/4-ClC6H4CO2- with 0.015 M HDAB, single sym. maxima (at both 25 and 35 °C) were obtained at [4-ClC6H4CO2Na] = 0.03 M. This is evidence for the existence of wormlike micelles/nanoparticles. However, the absence of a maximum in rheometric data for aqueous HAD+/C16E20/4-ClC6H4CO2- with 0.015 M HDAB and 0.006 M C16E20 at various [4-ClC6H4CO2Na] revealed the existence of spherical micelles. The experimental process involved the reaction of Phenyl Salicylate(cas: 118-55-8).Application In Synthesis of Phenyl Salicylate

The Article related to phenyl salicylate piperidinolysis kinetics, Physical Organic Chemistry: Other Reactions, Processes, and Spectra and other aspects.Application In Synthesis of Phenyl Salicylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On January 17, 1984, Meienhofer, Johannes A. published a patent.Application of 53838-27-0 The title of the patent was Immunopotentiating peptides. And the patent contained the following:

Peptides H-X-Glu-Asn-OH [X = null, Ala (I), Glu-Glu-Ala (II), Val-Glu-Glu-Ala, Val-Val-Glu-Glu-Ala] and their salts were prepared by known procedures. These di- to heptapeptides represent fragments of thymosin α1. Thus, I and II were prepared from their benzyl-protected derivatives by hydrogenolysis. I and II showed activity comparable to that of thymosin α1 in converting precursor T cells into steroid sensitive T1 cells or steroid resistant T2 cells. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Application of 53838-27-0

The Article related to immunopotentiation thymosin peptide fragment, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Application of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 14, 2006, Degrado, William F.; Bennett, Joel S.; Snyder, Seth Elliot; Choi, Sungwook published a patent.Application In Synthesis of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of prolyl dipeptides as inhibitors of the α2β1/gpIa-IIa integrin. And the patent contained the following:

The invention discloses novel compounds I [X is alkylidene; R1 is aralkylamino, aryl- or alkylsulfonylamino, carbalkoxymethyl, aralkoxycarbonylamino, NHSO2R2, where R2 is aryl, alkyl, aralkyl, aralkoxy, aralkylamino, arylamino, or alkylamino; R3 is halo, nitro, aryl, amino, alkyl, alkoxy, alkylsulfonyl, etc.; R4 is amino, hydroxy, aralkoxy, arylamino, aroylamino; R5 is H or alkyl; R6 is H or :O; A is SO2, PO2, CO2, CO; D is optional and may be one or more CH2 groups; E is aryl or heteroaryl; n, q are 0-2; m is 0 or 1; one of the three dashed-line portions may represent a double bond] or a stereoisomer, prodrug, pharmaceutically-acceptable salt, or N-oxide, which inhibit the integrin α2β1/GPIa-IIa receptor and are useful for the treatment of α2β1-affected disease states. Thus, prolyl peptide II was prepared and showed IC50 = 15 nM for inhibition of platelet adhesion to type I collagen. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Application In Synthesis of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to prolyl peptide preparation inhibitor integrin, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Application In Synthesis of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On September 4, 2012, Degrado, William F.; Bennett, Joel S.; Snyder, Seth Elliott; Choi, Sungwook published a patent.Recommanded Product: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Inhibitors of the α2β1/gpia-iia integrin. And the patent contained the following:

Novel compounds inhibiting the integrin α2β1/GPIa-IIa receptor are disclosed. Also disclosed are pharmaceutical compositions containing the compounds, as well as methods of their therapeutic use. The compounds disclosed are useful, inter alia, as inhibitors of integrin α2β1/GPIa-IIa-mediated activity. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Recommanded Product: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to prolyl peptide preparation inhibitor integrin, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Recommanded Product: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 31, 2020, Yemanyi, Felix; Vranka, Janice; Raghunathan, Vijay Krishna published an article.COA of Formula: C12H18O5 The title of the article was Glucocorticoid-induced cell-derived matrix modulates transforming growth factor β2 signaling in human trabecular meshwork cells. And the article contained the following:

Aberrant remodeling of trabecular meshwork (TM) extracellular matrix (ECM) may induce ocular hypertensive phenotypes in human TM (hTM) cells to cause ocular hypertension, via a yet unknown mechanism. Here, we show that, in the absence of exogenous transforming growth factor-beta2 (TGFβ2), compared with control matrixes (VehMs), glucocorticoid-induced cell-derived matrixes (GIMs) trigger non-Smad TGFβ 2 signaling in hTM cells, correlated with overexpression/activity of structural ECM genes (fibronectin, collagen IV, collagen VI, myocilin), matricellular genes (connective tissue growth factor [CTGF], secreted protein, acidic and rich in cysteine), crosslinking genes/enzymes (lysyl oxidase, lysyl oxidase-like 2-4, tissue transglutaminase-2), and ECM turnover genes/enzymes (matrix metalloproteinases-MMP2,14 and their inhibitors-TIMP2). However, in the presence of exogenous TGFβ2, VehMs and GIMs activate Smad and non-Smad TGFβ2 signaling in hTM cells, associated with overexpression of α-smooth muscle actin (α-SMA), and differential upregulation of aforementioned ECM genes/proteins with new ones emerging (collagen-I, thrombospondin-I, plasminogen activator inhibitor, MMP1, 9, ADAMTS4, TIMP1); with GIM-TGFβ2-induced changes being mostly more pronounced. This suggests dual glaucomatous insults potentiate profibrotic signaling/phenotypes. Lastly, we demonstrate type I TGFβreceptor kinase inhibition abrogates VehM-/GIM- and/or TGFβ2-induced upregulation of α-SMA and CTGF. Collectively, pathol. TM microenvironments are sufficient to elicit adverse cellular responses that may be ameliorated by targeting TGFβ2 pathway. The experimental process involved the reaction of Oxybis(ethane-2,1-diyl) bis(2-methylacrylate)(cas: 2358-84-1).COA of Formula: C12H18O5

The Article related to tgfbeta gim signaling human trabecular meshwork, Mammalian Hormones: Corticosteroid, Gonadal, and Placental Hormones and other aspects.COA of Formula: C12H18O5

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 30, 2017, Borger, Volker; Clarke, Colin; Hensel, Manfred published an article.Related Products of 3319-31-1 The title of the article was The use of new additives in the processing of white and black filled compounds based on the diamine crosslinking system. And the article contained the following:

The benefits of a new additive range for use in diamine crosslinkecl polymers from Schill+Seilacher ”Struktol” GmbH are demonstrated. Rubber Compounds were mixed based on AEM (Vamac) – and HNBR (HP Zetpol) polymers. Struktol HT 740, Struktol HT 750 or Struktol HT 760 demonstrated different activity levels towards the surface of active white fillers and were therefore able to improve the dispersion in colored compounds in addition, using the new Struktol additives, improvement in the processing of colored compounds also extended to com- pounds filled only with carbon black, with improved flow and significantly enhancing release performance. Results presented here in Vamac GLS and HP Zetpol can be adopted to HT-ACM polymer. The experimental process involved the reaction of Tris(2-ethylhexyl) benzene-1,2,4-tricarboxylate(cas: 3319-31-1).Related Products of 3319-31-1

The Article related to additive filler compound diamine crosslinking system, Synthetic Elastomers and Natural Rubber: Compounding and Processing and other aspects.Related Products of 3319-31-1

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics